Procainamide
Antiarrhythmics, Class Ia
- Drug class
- Antiarrhythmics, Class Ia
- Availability
- Prescription only
- Routes
- Intramuscular, Intravenous
- Markets covered
- 2
- Products on record
- 3
Overview
Plain-language summary, compiled from the cited regulatory records
Procainamide is an antiarrhythmic medication belonging to Class Ia [1]. It is approved for treating documented ventricular arrhythmias that are considered life-threatening [1]. These may include sustained ventricular tachycardia [1]. Due to its potential to cause new or worsened arrhythmias, procainamide is generally not recommended for less severe arrhythmias [1]. Treatment of individuals with asymptomatic ventricular premature contractions should be avoided [1].
Procainamide hydrochloride is available as an injection [1]. While no specific brand examples were provided in the data, the active ingredient may be marketed under various brand names.
This medication has been the subject of adverse event reports [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 2 | February 9, 2026 |
| CA Canada | Health Canada | 1 | March 22, 2025 |
USUnited States· FDA
2 products
Uses
INDICATIONS AND USAGE
Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended.
Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital.
Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. 5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks.
CACanada· Health Canada
1 product
1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [2].
Drug interactions
Known interactions involving Procainamide. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 312. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 0aac32fa-37b7-55… · revised November 21, 2023 [PDF]
- [2]Health Canada (DPD) · 02184486 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.